<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03793361</url>
  </required_header>
  <id_info>
    <org_study_id>EREMISS</org_study_id>
    <nct_id>NCT03793361</nct_id>
  </id_info>
  <brief_title>Phase II Study of Regorafenib as Maintenance Therapy</brief_title>
  <official_title>Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib®&#xD;
      to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas&#xD;
      experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as&#xD;
      1st line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized 1:1 using a centralized randomization software, assuring&#xD;
      concealment, with a minimization program controlling for the following factors:&#xD;
&#xD;
        -  Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological&#xD;
           subtype&#xD;
&#xD;
        -  Response to doxorubicin-based chemotherapy: partial response versus stable disease&#xD;
&#xD;
        -  Centers&#xD;
&#xD;
      The treatment will be administrated as long as it appears beneficial. Evaluations will be&#xD;
      made every 8 weeks until 6 months and then every 3 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    interim analysis&#xD;
  </why_stopped>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of regorafenib compared to placebo</measure>
    <time_frame>from the date of randomization to the date of first observed disease progression (according to RECIST 1.1 criteria) or death from any cause, up to 12 months after the beginning of the treatment</time_frame>
    <description>Progression-Free Survival will be measured from the date of randomization until the date of radiological progression (according to RECIST 1.1 criteria) or death (if death occurs before progression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of regorafenib compared to placebo</measure>
    <time_frame>from the date of randomization to the date of death from any cause</time_frame>
    <description>in terms of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of regorafenib compared to placebo</measure>
    <time_frame>from the date of randomization to the date of first observed disease progression (according to RECIST 1.1) or death from any cause, up to 12 months after the beginning of the treatment</time_frame>
    <description>Best response according to RECIST 1.1 evaluated by central radiological review: Complete Response, CR, or Partial Response, PR, achieved during the maintenance therapy. CR and PR will be counted as objective response to estimate the objective response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of regorafenib compared to placebo</measure>
    <time_frame>from the date of randomization to the date of death from any cause, up to 12 months after the beginning of the treatment</time_frame>
    <description>Time to start subsequent line of anticancer therapy defined as the time interval from the date of randomization to the date of start subsequent line of anticancer therapy. Patient data will be censored at the date of last follow-up visit for patients alive at last follow-up visit without having started subsequent line of anticancer therapy. Death without having started subsequent line of anticancer therapy will be counted as a competing event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of regorafenib</measure>
    <time_frame>Baseline, every 4 weeks, up to 12 months after the beginning of the treatment</time_frame>
    <description>Compared to placebo - Toxicity according to NCI-CTC AE V5.0 over the whole treatment duration plus 30 days, excluding AE unequivocally related to the disease under study or its progression. Adverse events of grade 3 or more (grade 3+) will be counted as severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the relative benefit/risk ratio</measure>
    <time_frame>up to 12 months</time_frame>
    <description>using the Q-TWiST approach - Quality-adjusted time without symptoms of disease or toxicity computed from survival times (overall survival and progression-free survival) and adverse events data (date of occurrence of grade 3+ adverse event classified as drug-related)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>assessment of the predictive value of SUMSCAN signature</measure>
    <time_frame>up to 12 months</time_frame>
    <description>genomic signature established on initial diagnostic biopsies or resection specimen and identifying sarcoma patients benefitting from anti-angiogenetic agents</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Metastatic Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.&#xD;
Provided by BAYER</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression&#xD;
Provided by BAYER</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically proven soft tissue sarcoma including leiomyosarcoma, synovial sarcoma&#xD;
             and other sarcomas&#xD;
&#xD;
          -  Patients in partial response or stable disease after 6 cycles of doxorubicin-based&#xD;
             first-line chemotherapy for metastatic/locally advanced soft tissue sarcoma&#xD;
&#xD;
          -  Metastatic/locally advanced disease not amenable to surgical resection with curative&#xD;
             intent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status =0 or 1&#xD;
&#xD;
          -  Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT&#xD;
             scan as defined by RECIST 1.1.&#xD;
&#xD;
          -  Available tumor tissue for translational research program&#xD;
&#xD;
          -  Adequate bone marrow, renal, and hepatic function, as evidenced by the following&#xD;
             within 7 days of study treatment initiation:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1,500/mm3&#xD;
&#xD;
          -  Platelets ≥100,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
          -  Serum creatinine ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥30 ml/min/1.73m2&#xD;
&#xD;
          -  AST and ALT ≤2.5 x ULN ( ≤5.0 × ULN for patients with liver involvement of their&#xD;
             cancer)&#xD;
&#xD;
          -  Bilirubin ≤1.5 X ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN with liver involvement of their cancer)&#xD;
&#xD;
          -  Lipase ≤1.5 x ULN&#xD;
&#xD;
          -  Spot urine must not show 1+ or more protein in urine or the patient will require a&#xD;
             repeat urine analysis. If repeat urinanalysis shows 1+ protein or more, a 24-hour&#xD;
             urine collection will be required and must show total protein excretion &lt;1000 mg/24&#xD;
             hours&#xD;
&#xD;
          -  INR/PTT ≤1.5 x ULN (Patients who are therapeutically treated with an agent such as&#xD;
             warfarin or heparin will be allowed to participate provided that no prior evidence of&#xD;
             underlying abnormality in coagulation parameters exists. Close monitoring of at least&#xD;
             weekly evaluations will be performed until INR/PTT is stable based on a measurement&#xD;
             that is pre-dose as defined by the local standard of care.)&#xD;
&#xD;
          -  Women of childbearing potential and male subjects must agree to use adequate&#xD;
             contraception for the duration of study participation and up to 3 months following&#xD;
             completion of therapy. Adequate contraception is defined as any medically recommended&#xD;
             method (or combination of methods) as per standard of care.&#xD;
&#xD;
          -  Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events&#xD;
             (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior&#xD;
             treatment from any previous drug/procedure related toxicity (except alopecia, anemia,&#xD;
             and hypothyroidism).&#xD;
&#xD;
          -  In the assessment of the investigator, patients are able to comply with study&#xD;
             requirements&#xD;
&#xD;
          -  Signed, IRB-approved written informed consent&#xD;
&#xD;
          -  Patient covered by the French &quot;Social Security&quot; regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy not allowing at least 6 cycles of&#xD;
             doxorubicin-based chemotherapy at metastatic stage&#xD;
&#xD;
          -  Complete response to 1st line chemotherapy for metastatic/locally advanced soft tissue&#xD;
             sarcoma&#xD;
&#xD;
          -  Disease progression during the 1st line of chemotherapy&#xD;
&#xD;
          -  Time interval between the last cycle of doxorubicin-based chemotherapy superior to 8&#xD;
             weeks&#xD;
&#xD;
          -  Primary bone sarcoma&#xD;
&#xD;
          -  All forms of liposarcoma&#xD;
&#xD;
          -  Some particular histologic types, i.e., PNET/Ewing, alveolar or embryonal&#xD;
             rhabdomyosarcoma, Perivascular epithelioid cell sarcoma (PECoMA), low grade&#xD;
             endometrial stromal tumor, desmoid tumor&#xD;
&#xD;
          -  Prior treatment with tyrosine kinase inhibitor&#xD;
&#xD;
          -  Known history of or concomitant malignancy likely to affect life expectancy in the&#xD;
             judgment of the investigator&#xD;
&#xD;
          -  Pregnant or breastfeeding patients. Women of childbearing potential must have a&#xD;
             pregnancy test performed a maximum of 7 days before start of treatment&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             before start of Day 1 of treatment&#xD;
&#xD;
          -  Active cardiac disease including any of the following: Congestive heart failure (New&#xD;
             York Heart Association [NYHA]) ≥Class 2, Unstable angina (angina symptoms at rest),&#xD;
             new-onset angina (begun within the last 3 months), Cardiac arrhythmias requiring&#xD;
             anti-arrhythmic therapy (beta blockers or digoxin are permitted)&#xD;
&#xD;
          -  Uncontrolled hypertension (Systolic blood pressure &gt;150 mmHg or diastolic pressure &gt;90&#xD;
             mmHg despite optimal medical management)&#xD;
&#xD;
          -  Arterial or venous thrombotic or embolic events such as myocardial infarction,&#xD;
             cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis,&#xD;
             or pulmonary embolism within 6 months of starting on study drug&#xD;
&#xD;
          -  Any hemorrhage or bleeding event &gt; Grade 4 within 4 weeks of start of treatment&#xD;
&#xD;
          -  Ongoing infection &gt;Grade 2 according to NCI Common Terminology Criteria for Adverse&#xD;
             Events version 5.0 (CTCAE v. 5.0)&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Known history of chronic hepatitis B or C&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event &gt; Grade 4&#xD;
             within 4 weeks of start of treatment&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Dehydration according to NCI-CTC v 4.0 Grade &gt;1&#xD;
&#xD;
          -  Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Inability to swallow oral medications, Any mal-absorption condition&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François LECLERC</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>June 21, 2023</last_update_submitted>
  <last_update_submitted_qc>June 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03793361
org study id: EREMISS
nct id: NCT03793361
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib®
      to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas
      experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as
      1st line chemotherapy.
Patients will be randomized 1:1 using a centralized randomization software, assuring
      concealment, with a minimization program controlling for the following factors:

        -  Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological
           subtype

        -  Response to doxorubicin-based chemotherapy: partial response versus stable disease

        -  Centers

      The treatment will be administrated as long as it appears beneficial. Evaluations will be
      made every 8 weeks until 6 months and then every 3 months
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: To assess the efficacy of regorafenib compared to placebo
time frame: from the date of randomization to the date of first observed disease progression (according to RECIST 1.1 criteria) or death from any cause, up to 12 months after the beginning of the treatment
description: Progression-Free Survival will be measured from the date of randomization until the date of radiological progression (according to RECIST 1.1 criteria) or death (if death occurs before progression).
measure: To assess the efficacy of regorafenib compared to placebo
time frame: from the date of randomization to the date of death from any cause
description: in terms of overall survival
measure: To assess the efficacy of regorafenib compared to placebo
time frame: from the date of randomization to the date of first observed disease progression (according to RECIST 1.1) or death from any cause, up to 12 months after the beginning of the treatment
description: Best response according to RECIST 1.1 evaluated by central radiological review: Complete Response, CR, or Partial Response, PR, achieved during the maintenance therapy. CR and PR will be counted as objective response to estimate the objective response rate (ORR)
measure: To assess the efficacy of regorafenib compared to placebo
time frame: from the date of randomization to the date of death from any cause, up to 12 months after the beginning of the treatment
description: Time to start subsequent line of anticancer therapy defined as the time interval from the date of randomization to the date of start subsequent line of anticancer therapy. Patient data will be censored at the date of last follow-up visit for patients alive at last follow-up visit without having started subsequent line of anticancer therapy. Death without having started subsequent line of anticancer therapy will be counted as a competing event.
measure: To assess the safety of regorafenib
time frame: Baseline, every 4 weeks, up to 12 months after the beginning of the treatment
description: Compared to placebo - Toxicity according to NCI-CTC AE V5.0 over the whole treatment duration plus 30 days, excluding AE unequivocally related to the disease under study or its progression. Adverse events of grade 3 or more (grade 3+) will be counted as severe adverse events
measure: To assess the relative benefit/risk ratio
time frame: up to 12 months
description: using the Q-TWiST approach - Quality-adjusted time without symptoms of disease or toxicity computed from survival times (overall survival and progression-free survival) and adverse events data (date of occurrence of grade 3+ adverse event classified as drug-related)
measure: assessment of the predictive value of SUMSCAN signature
time frame: up to 12 months
description: genomic signature established on initial diagnostic biopsies or resection specimen and identifying sarcoma patients benefitting from anti-angiogenetic agents
arm group label: Arm A
arm group type: Experimental
description: Regorafenib
arm group label: Arm B
arm group type: Placebo Comparator
description: Placebo
intervention type: Drug
intervention name: Regorafenib
description: Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
Provided by BAYER
arm group label: Arm A
other name: stivarga
intervention type: Drug
intervention name: Placebo
description: Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
Provided by BAYER
arm group label: Arm B
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Nicolas PENEL, PhD
role: Study Director
affiliation: Centre Oscar Lambret
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
responsible party type: Sponsor
mesh term: Sarcoma